Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

Trial Profile

Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs RNS 60 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Revalesio
  • Most Recent Events

    • 10 Apr 2017 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
    • 10 Apr 2017 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.
    • 10 Apr 2017 Planned initiation date changed from 1 Jan 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top